Pharmaceuticals, Biotechnology and Life Sciences
Several leaders of some of the largest pharmaceutical companies have met on Tuesday with the newly elected US president, Donald Trump to discuss industry related topics, agreeing that the talks were positive.
Akers Biosciences, a developer of rapid health information technologies, expects the total revenue for the 2016 year to be about…
A drug widely used to cure malaria has failed for the first time in patients being treated in Britain, raising questions over whether the parasite is becoming resistant to drugs, researchers said on Tuesday
U.S. President Donald Trump in a meeting on Tuesday with pharmaceutical executives called on them to manufacture more of their drugs in the United States and cut prices, while vowing to speed approval of new medicines and ease regulation.
The newly appointed president of the United States of America, Donald Trump said that he wants pharmaceutical companies to manufacture their products in America, during the meeting he held with leaders of some of the major drugmakers.
Driven by new products, including Trulicity, Cyramza, Jardiance and Taltz, Lilly’s volume-driven significant growth in 2016.
Onxeo, an oncology French-based focused drugmaker and a cancer researcher, the Institut Curie, have kicked off several cancer studies, to test the combination of radiotherapy, DNA repair inhibitors and immunotherapy.
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
India’s health ministry is likely to see a substantial increase in funding, after it warned that its programs were short of cash and sought more than $1.2 billion in additional money